CAS 780758-10-3
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
2 produits concernés.
Nimotuzumab
CAS :<p>Intereferes with EGFR ligand binding; cancer therapy</p>Degré de pureté :Min. 95%Couleur et forme :Clear LiquidNimotuzumab (powder)
CAS :<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Couleur et forme :Liquid
